Submission Details
| 510(k) Number | K142609 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | September 16, 2014 |
| Decision Date | December 18, 2014 |
| Days to Decision | 93 days |
| Submission Type | Traditional |
| Review Panel | Toxicology (TX) |
| Summary | Summary PDF |
K142609 is an FDA 510(k) clearance for the CR3 Keyless Split Sample Cup Nortriptyline-Buprenorphine, a Radioimmunoassay, Tricyclic Antidepressant Drugs (Class II — Special Controls, product code LFG), submitted by Guangzhou Wondfo Biotech Co., Ltd. (Guangzhou, CN). The FDA issued a Cleared decision on December 18, 2014, 93 days after receiving the submission on September 16, 2014. This device falls under the Toxicology review panel. Regulated under 21 CFR 862.3910.
| 510(k) Number | K142609 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | September 16, 2014 |
| Decision Date | December 18, 2014 |
| Days to Decision | 93 days |
| Submission Type | Traditional |
| Review Panel | Toxicology (TX) |
| Summary | Summary PDF |
| Product Code | LFG — Radioimmunoassay, Tricyclic Antidepressant Drugs |
| Device Class | Class II — Special Controls |
| CFR Regulation | 21 CFR 862.3910 |
| Definition | Intended To Measure Any Of The Tricyclic Antidepressant Drugs In Serum Or Urine. |